AR053809A1 - Combinacion de compuestos organicos - Google Patents
Combinacion de compuestos organicosInfo
- Publication number
- AR053809A1 AR053809A1 ARP060100468A ARP060100468A AR053809A1 AR 053809 A1 AR053809 A1 AR 053809A1 AR P060100468 A ARP060100468 A AR P060100468A AR P060100468 A ARP060100468 A AR P060100468A AR 053809 A1 AR053809 A1 AR 053809A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- combination
- angiotensin
- neutral endopeptidase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Combinacion que comprende: i) un inhibidor de renina, o una sal farmacéuticamente aceptable del mismo; ii) un inhibidor de endopeptidasa neutra (NEP), o una sal farmacéuticamente aceptable del mismo; y opcionalmente cuando menos un agente terapéutico selecciona a partir del grupo que consiste en: a) un diurético, o una sal farmacéuticamente aceptable del mismo; y b) un bloqueador del receptor de angiotensina II (ARB), o una sal farmacéuticamente aceptable del mismo; para la prevencion, demora de establecimiento, y/o tratamiento de una enfermedad o condicion mediada por la actividad de la angiotensina II y/o de la endopeptidasa neutra, cuyo método comprende administrar a una animal de sangre caliente que lo necesite, una cantidad terapéuticamente efectiva de una combinacion de la presente. Composicion farmacéutica, método, y uso.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65232505P | 2005-02-11 | 2005-02-11 | |
| US65510205P | 2005-02-22 | 2005-02-22 | |
| US67009005P | 2005-04-11 | 2005-04-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR053809A1 true AR053809A1 (es) | 2007-05-23 |
Family
ID=36793671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060100468A AR053809A1 (es) | 2005-02-11 | 2006-02-09 | Combinacion de compuestos organicos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20080119557A1 (es) |
| EP (1) | EP1863467A2 (es) |
| JP (1) | JP2008530101A (es) |
| KR (1) | KR20070102544A (es) |
| AR (1) | AR053809A1 (es) |
| AU (1) | AU2006212772B2 (es) |
| BR (1) | BRPI0606996A2 (es) |
| CA (1) | CA2596485A1 (es) |
| GT (1) | GT200600055A (es) |
| IL (1) | IL184426A0 (es) |
| MA (1) | MA29326B1 (es) |
| MY (1) | MY146830A (es) |
| NO (1) | NO20074509L (es) |
| NZ (1) | NZ556275A (es) |
| PE (1) | PE20060999A1 (es) |
| TN (1) | TNSN07312A1 (es) |
| TW (1) | TW200716081A (es) |
| WO (1) | WO2006086456A2 (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2580862A1 (en) * | 2004-10-08 | 2006-04-20 | Novartis Ag | Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure |
| WO2007051007A2 (en) * | 2005-10-28 | 2007-05-03 | Novartis Ag | Combination of antihypertensives with cholesterol-lowering agent |
| AR057882A1 (es) * | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| GB0612540D0 (en) * | 2006-06-23 | 2006-08-02 | Novartis Ag | Galenical formulations of organic compounds |
| PL2121578T3 (pl) | 2007-01-12 | 2017-02-28 | Novartis Ag | Sposób wytwarzania kwasu 5-bifenyl-4-amino-2-metylo-pentanowego |
| TW200838501A (en) | 2007-02-02 | 2008-10-01 | Theravance Inc | Dual-acting antihypertensive agents |
| TWI448284B (zh) | 2007-04-24 | 2014-08-11 | Theravance Inc | 雙效抗高血壓劑 |
| TWI406850B (zh) | 2007-06-05 | 2013-09-01 | Theravance Inc | 雙效苯并咪唑抗高血壓劑 |
| JP2010538071A (ja) | 2007-09-07 | 2010-12-09 | セラヴァンス， インコーポレーテッド | 二重作用性降圧剤 |
| WO2009040427A1 (en) * | 2007-09-28 | 2009-04-02 | Novartis Ag | Galenical formulations of organic compounds |
| JP2010540547A (ja) * | 2007-09-28 | 2010-12-24 | ノバルティス アーゲー | アリスキレンおよびバルサルタンのガレヌス製剤 |
| CA2697229A1 (en) * | 2007-09-28 | 2009-04-02 | Novartis Ag | Galenical formulations of organic compounds |
| EP2225210B1 (en) | 2007-12-11 | 2012-04-25 | Theravance, Inc. | Dual-acting benzoimidazole derivative and their use as antihypertensive agents |
| EP2297113A1 (en) | 2008-04-29 | 2011-03-23 | Theravance, Inc. | Dual-acting antihypertensive agents |
| WO2009143403A1 (en) * | 2008-05-23 | 2009-11-26 | Targacept, Inc. | Combination therapy for the management hypertension |
| US20100093603A1 (en) * | 2008-07-17 | 2010-04-15 | Kenneth Baker | Use of organic compounds |
| EP2334651A2 (en) | 2008-07-24 | 2011-06-22 | Theravance, Inc. | Dual-acting antihypertensive agents |
| DE102008059206A1 (de) | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
| AR075881A1 (es) * | 2009-03-20 | 2011-05-04 | Novartis Ag | Composicion farmaceutica.metodo de preparacion |
| EP2594557B1 (en) * | 2009-05-28 | 2016-08-10 | Novartis AG | Substituted aminopropionic derivatives as neprilysin inhibitors |
| AU2010251948A1 (en) * | 2009-05-28 | 2011-12-01 | Novartis Ag | Substituted aminobutyric derivatives as neprilysin inhibitors |
| ES2611107T3 (es) | 2009-07-07 | 2017-05-04 | Theravance Biopharma R&D Ip, Llc | Agentes antihipertensivos de pirazol, de doble acción |
| ES2441419T3 (es) | 2009-07-22 | 2014-02-04 | Theravance, Inc. | Agentes antihipertensivos de doble acción basados en oxazol |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
| JP2013517295A (ja) | 2010-01-19 | 2013-05-16 | セラヴァンス， インコーポレーテッド | 二重に作用するチオフェン、ピロール、チアゾールおよびフラン抗高血圧症薬 |
| EP2609075B1 (en) | 2010-08-23 | 2016-03-16 | Novartis AG | Process for the preparation of intermediates for the manufacture of nep inhibitors |
| US8877815B2 (en) * | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
| US8673974B2 (en) * | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| AU2013304949C1 (en) | 2012-08-24 | 2020-12-24 | Novartis Ag | NEP inhibitors for treating diseases characterized by atrial enlargement or remodeling |
| EA026989B1 (ru) | 2013-02-14 | 2017-06-30 | Новартис Аг | Производные замещенной бисфенилбутановой кислоты в качестве ингибиторов nep с улучшенной in vivo эффективностью |
| PL2956464T3 (pl) | 2013-02-14 | 2018-08-31 | Novartis Ag | Podstawione pochodne bisfenylowe kwasu butanowofosfonowego jako inhibitory nep (neutralnej endopeptydazy) |
| CN105348209B (zh) | 2015-12-09 | 2017-12-26 | 浙江天宇药业股份有限公司 | 一种抗心衰药lcz696的制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992013564A1 (en) * | 1991-02-06 | 1992-08-20 | Schering Corporation | Combination of an angiotensin ii antagonist or renin inhibitor with a neutral endopeptidase inhibitor |
| US5217996A (en) * | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
| DE19750529A1 (de) * | 1997-11-14 | 1999-05-20 | Basf Ag | Neue heterocyclisch substituierte alpha-Hydroxycarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten |
| US6506785B2 (en) * | 1998-05-22 | 2003-01-14 | Pfizer, Inc. | Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives |
| US8168616B1 (en) * | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| US7468390B2 (en) * | 2002-01-17 | 2008-12-23 | Novartis Ag | Methods of treatment and pharmaceutical composition |
| CN1615134A (zh) * | 2002-01-17 | 2005-05-11 | 诺瓦提斯公司 | 含有缬沙坦和nep抑制剂的药物组合物 |
| NZ536555A (en) * | 2002-05-17 | 2007-03-30 | Novartis Ag | Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
| GB0212412D0 (en) * | 2002-05-29 | 2002-07-10 | Novartis Ag | Combination of organic compounds |
| CL2004000544A1 (es) * | 2003-03-18 | 2005-01-28 | Pharmacia Corp Sa Organizada B | Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati |
| CL2004000545A1 (es) * | 2003-03-18 | 2005-01-28 | Pharmacia Corp Sa Organizada B | Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul |
| US20040214804A1 (en) * | 2003-04-25 | 2004-10-28 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and an anti-obesity agent |
-
2006
- 2006-02-07 MY MYPI20060499A patent/MY146830A/en unknown
- 2006-02-09 JP JP2007555186A patent/JP2008530101A/ja active Pending
- 2006-02-09 US US11/813,530 patent/US20080119557A1/en not_active Abandoned
- 2006-02-09 CA CA002596485A patent/CA2596485A1/en not_active Abandoned
- 2006-02-09 NZ NZ556275A patent/NZ556275A/en not_active IP Right Cessation
- 2006-02-09 BR BRPI0606996-7A patent/BRPI0606996A2/pt not_active IP Right Cessation
- 2006-02-09 WO PCT/US2006/004401 patent/WO2006086456A2/en active Application Filing
- 2006-02-09 KR KR1020077018445A patent/KR20070102544A/ko not_active Application Discontinuation
- 2006-02-09 AU AU2006212772A patent/AU2006212772B2/en not_active Ceased
- 2006-02-09 PE PE2006000152A patent/PE20060999A1/es not_active Application Discontinuation
- 2006-02-09 EP EP06734563A patent/EP1863467A2/en not_active Withdrawn
- 2006-02-09 AR ARP060100468A patent/AR053809A1/es not_active Application Discontinuation
- 2006-02-10 GT GT200600055A patent/GT200600055A/es unknown
- 2006-02-10 TW TW095104610A patent/TW200716081A/zh unknown
-
2007
- 2007-07-05 IL IL184426A patent/IL184426A0/en unknown
- 2007-08-10 TN TNP2007000312A patent/TNSN07312A1/en unknown
- 2007-09-06 NO NO20074509A patent/NO20074509L/no not_active Application Discontinuation
- 2007-09-10 MA MA30209A patent/MA29326B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MY146830A (en) | 2012-09-28 |
| NO20074509L (no) | 2007-11-12 |
| MA29326B1 (fr) | 2008-03-03 |
| AU2006212772B2 (en) | 2009-06-11 |
| WO2006086456A3 (en) | 2007-11-15 |
| TNSN07312A1 (en) | 2008-12-31 |
| JP2008530101A (ja) | 2008-08-07 |
| US20080119557A1 (en) | 2008-05-22 |
| TW200716081A (en) | 2007-05-01 |
| PE20060999A1 (es) | 2006-11-21 |
| WO2006086456A2 (en) | 2006-08-17 |
| EP1863467A2 (en) | 2007-12-12 |
| NZ556275A (en) | 2011-04-29 |
| CA2596485A1 (en) | 2006-08-17 |
| IL184426A0 (en) | 2007-10-31 |
| KR20070102544A (ko) | 2007-10-18 |
| AU2006212772A1 (en) | 2006-08-17 |
| GT200600055A (es) | 2006-09-07 |
| BRPI0606996A2 (pt) | 2009-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR053809A1 (es) | Combinacion de compuestos organicos | |
| BRPI0618371A2 (pt) | combinação de compostos orgánicos | |
| WO2008050329A3 (en) | Novel sirnas and methods of use thereof | |
| AR059575A1 (es) | Metodo para el tratamiento de enfermedades inflamatorias | |
| WO2006059245A3 (en) | Compounds for the treatment of cns and amyloid associated diseases | |
| WO2009044392A3 (en) | Novel sirna structures | |
| CR9721A (es) | Compuestos de carbamato para utilizar en el tratamiento de desordenes neurodegenerativos | |
| WO2006037031A3 (en) | Formulations and methods for treatment of inflammatory diseases | |
| ATE297723T1 (de) | Pharmazeutische zusammensetzung enthaltend ein 5- aminolaevulinsäure-ester als photochemotherapeutikum und ein mucoadhäsivum | |
| NO20075344L (no) | Metforminbaserte fremgangsmater og utforminger for behandling av kronisk forstoppelse | |
| ECSP10010160A (es) | Composiciones farmaceuticas de accion doble basadas en super-estructuras de antagonista/bloqueador del receptor de angiotensina (arb) e inhibidor de endopeptidasa neutra (nep) | |
| CR7928A (es) | Medicamento para la profilaxis y el tratamiento de arteriosclerosis e hipertension | |
| JP2008508279A5 (es) | ||
| CL2008000593A1 (es) | Uso de compuestos derivados de heterociclos sustituidos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad aterosclerotica de las arterias entre otras enfermedades. | |
| EP3276004A3 (en) | Methods for treating chronic kidney disease | |
| WO2006083780A3 (en) | Glucuronidated nebivolol | |
| WO2006061715A3 (en) | Methylene inhibitors of matrix metalloproteinase | |
| WO2006131874A3 (en) | Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury | |
| AR052322A1 (es) | Compuestos de n-benzoil-estaurosporina, procesos para su preparacion y composicion farmaceutica | |
| WO2007106884A3 (en) | Methods of treating muscular wasting diseases using nf-kb activation inhibitors | |
| WO2008070010A3 (en) | Hydroxylamine derivatives for the treatment of stroke | |
| UY31417A1 (es) | Una composicion farmacéutica y un proceso para dicha composicion farmacéutica | |
| WO2005020919A3 (en) | Method of treatment and bioassay involving macrophage migration inhibitory factor (mif) as cardiac-derived myocardial depressant factor | |
| WO2008073466A3 (en) | Alpha b-crystallin as a therapy for inflammation | |
| WO2008031835A3 (en) | Method of treating autoimmune diseases using vegf-pathway inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |